Updated

A Wall Street analyst has identified CRISPR Therapeutics as trading in a favorable entry zone and raised a price target implying up to 85% potential upside from current levels. The bullish call on the gene-editing therapeutics company reflects analyst conviction that recent trading patterns have created an attractive opportunity for investors.